Rate My Professor Katharina Robichon

An immunologist specializing in autoimmune diseases and with expertise in persistent viral infections, Dr Robichon studies factors shaping disease onset, progression, and treatment response, particularly in multiple sclerosis and rheumatoid arthritis. Her research employs full-spectrum flow cytometry and molecular techniques to characterize immune cell phenotypes, explore links between chronic viral infections and treatment outcomes, and investigate therapy mechanisms on immune cells. Key publications include 'Monitoring treatment-associated receptor expression in multiple sclerosis using a newly developed panel for spectral flow cytometry' (Cytometry Part A, 2025, co-authored with Taylor, Milner, Hally, and La Flamme); 'Nalmefene enhances the remyelinating ability of nalfurafine when administered therapeutically at very low doses during experimental autoimmune encephalomyelitis' (Clinical & Translational Immunology, 2025, co-authored with Denny, Templeton, Kiernan, Prisinzano, Kivell, and La Flamme); 'Development and application of an LC-MS method for the pharmacokinetics and pharmacodynamics of oral therapeutic efficacy of nalfurafine' (Basic & Clinical Pharmacology & Toxicology, 2026, co-authored with Sondhauss, Kiernan, Morizzi, Wright, Prisinzano, Kivell, and La Flamme); and earlier works such as 'Clozapine reduces infiltration into the CNS by targeting migration in experimental autoimmune encephalomyelitis' (Journal of Neuroinflammation, 2020). She received the Australian Society for Immunology Career Advancement Award and was a finalist for the Otago University Students' Association Supervisor of the Year award.